Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Imatinib Teva

- PMLiVE

EMA brings transparency to its committee proceedings

Publishes meeting minutes of CHMP and two other advisory groups

- PMLiVE

CHMP turns down drugs for MS, cancer and muscular dystrophy

Negative EU recommendations for Teva, AB Science and PTC Therapeutics

Novartis building

CHMP denies Novartis’ heart failure drug

Panel refuses to recommend serelaxin for use in EU

- PMLiVE

GSK’s diabetes drug among CHMP recommendations

EMA committee also backs drugs from Bayer, Takeda and Linepharma France

Novartis building

CHMP backs Xolair for severe hives

Novartis set to expand indications for asthma drug

Novartis building

New York plant set to close as Novartis continues cutbacks

More than 500 employees face the axe

- PMLiVE

Biocon plans February launch for first biosimilar Herceptin

Set to market own version of breast cancer drug in India

- PMLiVE

Novartis cancer chief Hoppenot leaves for top job at Incyte

He ends 10-year spell at Swiss pharma giant

- PMLiVE

Teva names Vigodman CEO and makes bid for NuPathe

Israeli pharma company confirms Jeremy Levin’s replacement

- PMLiVE

Key Teva shareholder backs Vigodman as next CEO

Board director tipped to replace Jeremy Levin at Israeli pharma firm

Biogen Idec building

Biogen Idec licenses anti-TNF biosimilars

Treatment prospects emerge from joint venture with Samsung Biologics

- PMLiVE

Teva’s vice chair steps down

Amir Elstein to take over from Moshe Many

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links